Hand-out
Press Releases
Blue Earth Therapeutics Reports Key Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial
− Data from the Phase 1 trial in metastatic prostate cancer suggest potential for highly optimized pharmacokinetics